Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018)
Cogent Biosciences' (COGT) quarterly Non-Current Deffered Revenue came in at $748000.0 in Q4 2018, down 91.42% year-on-year from $8.7 million in Q4 2017, and down 14.12% on a QoQ basis from $871000.0 in Q3 2018.
Cogent Biosciences (COGT) Non-Current Deffered Revenue (2017 - 2018) Analysis & Trends
Cogent Biosciences (COGT) has 2 years of Non-Current Deffered Revenue data on file, last reported at $748000.0 in Q4 2018.
- On a quarterly basis, Non-Current Deffered Revenue fell 91.42% year-over-year to $748000.0 in Q4 2018; TTM through Dec 2018 was $748000.0, a 91.42% decrease from a year earlier, with the FY2018 full-year figure at $748000.0, down 91.42% from the prior year.
- Non-Current Deffered Revenue for Q4 2018 stood at $748000.0, down from $871000.0 in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for COGT reached as high as $8.7 million in Q4 2017 and fell as low as $346000.0 in Q2 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 225.10 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Cogent Biosciences | 6.87 Bn | 6.87 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 748,000.00 |
| Sep 30, 2018 | 871,000.00 |
| Jun 30, 2018 | 346,000.00 |
| Mar 31, 2018 | 902,000.00 |
| Dec 31, 2017 | 8.71 Mn |